Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.

Revenue
+4.29%
EPS
+2.17%
Free cash flow
+27.0%
Total debt
−18.1%

Quarter to September 2026, against a year earlier

150.97 8.46 −5.31%
Market cap
$16.8B
P/E
71.9×
Fwd P/E
66.2×
Dividend yield
0.19%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
72.80 52.98 41.92 46.51

+8 more quarters

P/S ratio
5.80 4.26 3.38 3.95
P/FCF ratio
28.55 21.97 19.73 22.35
P/Operating CF
102.34 64.68 85.04 61.97
P/B ratio
2.36 1.72 1.36 1.56
EV/Sales
6.69 5.01 4.19 4.75
EV/EBITDA
25.36 18.82 15.62 17.71
EV/FCF
32.93 25.83 24.46 26.91
Current Ratio
2.65 1.80 1.72 1.68
Net Debt/EBITDA
0.00 11.33 12.89 10.66
Debt/Equity
0.36 0.44 0.45 0.44
Earnings Yield
1.37% 1.89% 2.39% 2.15%
Free Cash Flow Yield
3.50% 4.55% 5.07% 4.47%
Free Cash Flow per Share
0.00 1.65 0.93 1.39
Book value per Share
0.00 64.78 64.22 62.21
Free Cash Flow
152.36 183.91 104.46 161.79
EV/EBIT
52.87 40.68 33.71 38.07
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026